- Home
- SILC vs TIL Comparison
SILC vs TIL Comparison
Compare SILC & TIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SILC | TIL |
|---|---|---|
| Founded | 1987 | 2018 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Computer Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 86.3M | 74.7M |
| IPO Year | 1994 | 2021 |
Fundamental Metrics
Financial Performance| Metric | SILC | TIL |
|---|---|---|
| Price | $15.75 | $7.05 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 4 |
| Target Price | N/A | ★ $125.00 |
| AVG Volume (30 Days) | 33.4K | ★ 259.5K |
| Earning Date | 01-29-2026 | 03-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $59,509,000.00 | N/A |
| Revenue This Year | $6.48 | N/A |
| Revenue Next Year | $14.36 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $12.44 | $5.67 |
| 52 Week High | $19.37 | $42.79 |
Technical Indicators
Market Signals| Indicator | SILC | TIL |
|---|---|---|
| Relative Strength Index (RSI) | 57.80 | 31.14 |
| Support Level | $14.77 | $6.91 |
| Resistance Level | $15.99 | $7.36 |
| Average True Range (ATR) | 0.74 | 0.61 |
| MACD | 0.13 | -0.10 |
| Stochastic Oscillator | 66.42 | 19.34 |
Price Performance
Historical ComparisonAbout SILC Silicom Ltd
Silicom Ltd designs and manufactures networking and data infrastructure solutions for various servers, server-based systems, and communications devices. Its product categories consist of Server Adapters, Edge Networking Solutions, FPGA-Based Cards, x86 Open Appliances, Bypass Switches, and TAPs. Geographically, it derives a majority of its revenue from North America and also has a presence in Europe and Asia-Pacific.
About TIL Instil Bio Inc.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.